Lyon: Maintain Outperform rating on WuXi Biologics (02269.HK), target price raised to HK$34.8

According to the Zhitong Finance and Economics APP, it was reported that Lyon released a research report stating that in addition to development and production, potential royalty fees and milestone fees are expected to become key drivers of long-term growth for WuXi Biologics (02269.HK). Accordingly, revenue forecasts for 2025 to 2027 have been raised by 2% to 9%, and net profit forecasts for 2026 to 2027 have been raised by 6% to 12% to reflect strong mid-term performance and steady order growth. The target price has been raised from 28.8 Hong Kong dollars to 34.8 Hong Kong dollars, maintaining a "outperform the market" rating.